Thromboxane A2

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 20, 2024
Biotechnology, General Health, Pharmaceutical, Health, Toxicity, Growth, Ovarian cancer, Radiopharmaceutical, Patient, Anal cancer, Bicycle, McKinsey & Company, Head, Cervical cancer, EV, Neoplasm, ATM, Therapy, Food and Drug Administration, TNBC, Net, Former, CMC, Thromboxane A2, Immune system, NSCLC, MUC, Peripheral neuropathy, SunOpta, Safety, Ovary, Participation, Knowledge, Novartis, Lazard, BRC, FDA, Cancer, Food, Pembrolizumab, Government, ADC, Brentuximab vedotin, CD137, Pharmaceutical industry

Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent corporate updates.
  • We continue to demonstrate our ability to develop highly differentiated, precision-guided therapeutics that may offer greater tolerability and lead to enhanced benefit for patients,” said Kevin Lee, Ph.D., CEO of Bicycle Therapeutics.
  • Validating the company’s Bicycle® Radio Conjugates (BRC™) pipeline and partner for success, with updates expected from its wholly owned BRC program by mid-2024.
  • Advancing the company’s Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) immune-oncology pipeline through innovative partnerships.

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Webcast, MT1-MMP, Peripheral neuropathy, Brain, Safety, Immune system, Cervical cancer, Food, Therapy, Toxicity, Head, Diabetic neuropathy, Nobel Prize, Patient, CD137, Bicycle, FDA, Non-small-cell lung cancer, Pembrolizumab, Neoplasm, Ionis, Investigational New Drug, Brentuximab vedotin, MUC, ORR, Ovary, Anal cancer, Cancer, Ovarian cancer, Toxic leukoencephalopathy, Pain, R, Drug combination, EV, Central nervous system, TNBC, NSCLC, BRC, Pharmaceutical industry, Vaccine, Birth control, Medical imaging, Thromboxane A2

“In totality, the data support the emerging differentiated profile of our Bicycle® molecules, paving the way to deliver best-in-class or first-in-class therapies for many cancers.

Key Points: 
  • “In totality, the data support the emerging differentiated profile of our Bicycle® molecules, paving the way to deliver best-in-class or first-in-class therapies for many cancers.
  • BT8009 is a Nectin-4 Bicycle toxin conjugate (BTC®) designed to overcome the significant toxicity associated with other toxin conjugate approaches.
  • Over 2024, Bicycle Therapeutics intends to generate early human imaging data from its wholly owned BRC pipeline.
  • Bicycle Therapeutics will continue to develop Bicycle® molecules to address disease outside of oncology through innovative partnerships.

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day

Retrieved on: 
Thursday, November 2, 2023
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, ATM, Food, Progression-free survival, Public offering, Therapy, Thromboxane A2, Transitional epithelium, Bicycle, Pembrolizumab, CD137, CMC, PFS, Research and development, Participation, Exercise, R, RSVP, Novartis, Webcast, ORR, BTC, Food and Drug Administration, Pharmaceutical industry, Vaccine, Life insurance, Cryptocurrency, Bayer, Chemistry

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2023, and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2023, and provided recent corporate updates.
  • “In the third quarter, we took important steps toward achieving our goal of quickly getting our novel therapies to those who need them.
  • In September, Bicycle Therapeutics announced the company will proceed with its plan to expedite development of BT8009 for metastatic bladder cancer following recent discussions with the FDA.
  • In addition, the company also received net proceeds from Bicycle’s at-the-market (ATM) offering program during the third quarter of 2023 totaling $19.4 million.

Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023

Retrieved on: 
Thursday, May 11, 2023
Research, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Other Science, Science, Oncology, Radioactive decay, Therapy, Neoplasm, Survival, Clinical Cancer Research, Toxicity, Bicycle, Duan, Patient, Hematology, Cancer, Mouse, Johns Hopkins, Thromboxane A2, Pharmaceutical industry, Medical imaging

Bicycle Therapeutics plc (NASDAQ: BCYC) and Orano Med, two biotechnology companies respectively, announce pre-clinical results.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC) and Orano Med, two biotechnology companies respectively, announce pre-clinical results.
  • Bicycle is pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology and Orano Med is developing innovative radioligand therapies with lead-212 in oncology.
  • The results were presented at TIDES 2023 in San Diego, CA and can be accessed here .
  • “We are encouraged by the preclinical results that were presented at TIDES 2023 and are excited by the potent anti-tumor activity observed with this molecule,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.

Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, Pharmaceutical, Health, Clinical trial, Breast cancer, Society, Therapy, Thromboxane A2, Research, American Society of Clinical Oncology, Annual general meeting, Immunotherapy, FDA, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, CD137, SITC, FTD, ASCO, Cancer, Food, Phase, Net, Lung, Vaccine, Pharmaceutical industry, Cryptocurrency, Bicycle

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent corporate updates.
  • In February 2023, Bicycle presented monotherapy Phase I dose escalation results of the ongoing Phase I/II trial of BT8009, a novel Bicycle Toxin Conjugate targeting Nectin-4, at the ASCO GU Cancers Symposium.
  • BT8009 demonstrated anti-tumor activity in heavily pre-treated urothelial, lung and breast cancer patients with signs of differentiation compared to antibody-based approaches.
  • In September 2022, Bicycle announced results from the Phase I dose escalation portion of the ongoing Phase I/II trial in patients with advanced solid tumors.

Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Bicycle, Annual general meeting, Date, Immunotherapy, CD137, Drug development, Therapy, NASDAQ, Thromboxane A2, BTC, Cancer research, Biotechnology, Time, Industry, Society, MT1-MMP, SITC, Fine chemical, Animal

Details on Bicycles poster presentations at SITC are as follows:

Key Points: 
  • Details on Bicycles poster presentations at SITC are as follows:
    Date and Time: Thursday, November 10 at 9 a.m.
  • ET
    Presenters: Kristin Hurov and Lia Luus, Bicycle Therapeutics
    Date and Time: Friday, November 11 at 9 a.m.
  • Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry.
  • Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.

Atreca to Present at Upcoming Investor Conferences

Retrieved on: 
Monday, November 7, 2022
SAN, GLOBE, Private Securities Litigation Reform Act, Event, U.S. Securities and Exchange Commission, Risk, Research, SEC, Annual report, Compte rendu, NASDAQ, Antibody, Company, Neoplasm, Patient, Immune system, Therapy, Security (finance), Vaccine, Thromboxane A2

An archived replay of each presentation will be available on the Company's website for 30 days following the live broadcast.

Key Points: 
  • An archived replay of each presentation will be available on the Company's website for 30 days following the live broadcast.
  • Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform.
  • A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients, and ATRC-301 is in IND-enabling studies.
  • For more information on Atreca, please visit www.atreca.com .

Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update

Retrieved on: 
Tuesday, November 8, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, Neoplasm, Ovarian cancer, NASDAQ, BTC, U.S. Securities and Exchange Commission, CPI, Patient, SEC, Bicycle, Private Securities Litigation Reform Act, Biotechnology, Thromboxane A2, Clinical trial, NSCLC, RECIST, MT1-MMP, Large-cell lung carcinoma, Forward-looking statement, CD137, Drug development, MRCP, Cisplatin, Kidney, Cancer research, Cell, Squamous cell carcinoma, Therapy, Risk, Phase II, Security (finance), Pharmaceutical industry, UC, Phase

Dosing our first patient in the Phase II expansion portion of the BT8009 trial is a key development milestone for Bicycle, said Kevin Lee, Ph.D., Chief Executive Officer.

Key Points: 
  • Dosing our first patient in the Phase II expansion portion of the BT8009 trial is a key development milestone for Bicycle, said Kevin Lee, Ph.D., Chief Executive Officer.
  • Two doses have been selected as the recommended Phase II doses (RP2Ds): 5mg/m2 weekly and 7.5mg/m2 2-weeks on, 1-week off (over a 21-day cycle).
  • The Phase II multi-center, open label trial will evaluate BT8009 administered at the RP2Ds of 5mg/m2 and 7.5mg/m2.
  • The ongoing dose expansion includes cohorts evaluating the activity of BT8009 in CPI combination cohorts as well as in cohorts of patients with renal impairment.

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Friday, November 4, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, CD137, Biotechnology, Bicycle, Piper Sandler Companies, MT1-MMP, BTC, Investor, Conference, Cancer research, Drug development, NASDAQ, Thromboxane A2, Pharmaceutical industry

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate in the following investor conferences in November and December:

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate in the following investor conferences in November and December:
    Cowens 6th Annual IO Next Summit on Friday, November 11, 2022; fireside chat at 9:10 a.m.
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.
  • Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials.
  • Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.

Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 3, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Genentech, Peripheral neuropathy, Journal, Private Securities Litigation Reform Act, Phase, Therapy, Neck, Medicinal chemistry, CD137, Biotechnology, MT1-MMP, BTC, Incidence, U.S. Securities and Exchange Commission, Toxic leukoencephalopathy, Journal of Medicinal Chemistry, COVID-19, Esophageal cancer, Ovary, Head, Research, Molecular Cancer Research, Rash, Clinical trial, Cancer research, Forward-looking statement, Cancer, NASDAQ, American Association for Cancer Research, Non-small-cell lung carcinoma, Drug development, Risk, Program, Technology, Security (finance), Thromboxane A2, SEC, Treatment, Patient, Triple-negative breast cancer, Pharmaceutical industry, Bicycle

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.
  • We are encouraged by the continued clinical progress across our pipeline, said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.
  • In September, Bicycle announced top-line results from the Phase I dose escalation portion of its Phase I/II trial of BT5528, a Bicycle Toxin Conjugate (BTC) targeting EphA2, in patients with advanced solid tumors.
  • In June 2022, Bicycle announced the dosing of the first patient in the Phase II dose expansion portion of the Phase I/II trial.